2016
Psoriasis
Sponsor: AbbVie | Boehringer Ingelheim
BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
Phase: Phase 3
Start Date: February 2016
End Date: September 2017
Psoriasis
Sponsor: AbbVie | Boehringer Ingelheim
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
Phase: Phase 3
Start Date: February 2016
End Date: July 2018
Acne Vulgaris
Sponsor: Cassiopea SpA
An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris
Phase: Phase 3
Start Date: March 2016
End Date: December 2017
Actinic Keratosis
Sponsor: DUSA Pharmaceuticals, Inc.
Microneedle Lesion Preparation Prior to ALA-PDT for AK on Face
Phase: Phase 2
Start Date: March 2016
End Date: September 2016
Atopic Dermatitis
Sponsor: Pfizer
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Phase: Phase 2
Start Date: April 2016
End Date: May 2017
Plaque Psoriasis
Sponsor: Eli Lilly and Company
A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis
Phase: Phase 2
Start Date: September 2016
End Date: February 2019